This Sources Sought opportunity from Department Of Health And Human Services was posted on April 20, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

RRPV BoNT-NMJ

Closed

SSN-BARDA-04202026Federal

Submission Closed05/11/2026, 05:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Federal

Pharmacology and Pain Drug Development SMEThis subcontract opportunity through the Department of Health and Human Services Omas Strategic Buying Center seeks a subject matter expert in pharmacology and pain to support prime contractors on NIH HEAL Initiative projects. The selected expert will provide executive-level guidance on small molecule and biologic therapeutics, focusing on drug discovery and pharmacology-related trials for nervous system conditions. Key responsibilities include performing strategic programmatic reviews, evaluating milestones, and providing mentorship. The role requires the delivery of strategic recommendations and milestone evaluations through formal committee reports. Performance will take place in Bethesda, and the opportunity is categorized under NAICS code 541714. Interested parties should note the response deadline of November 3, 2026.

Omas Strategic Buying Center - Professional Services

POSTED

DEADLINE

Precision Prevention & Biological Pathway ResearchThe Precision Prevention and Biological Pathway Research subcontract supports prime contractors on Defense Health Agency Alzheimer’s Research Program projects. The primary objective is to conduct research linking service-related exposures to AD/ADRD biological pathways by quantifying military-relevant risk factors. This technical work involves the use of proteomics tools and genomic sequencing to map these biological pathways, culminating in the delivery of detailed research reports and data. Performance of this contract takes place in Frederick, Maryland, under NAICS code 541714. Due to the nature of the study, the contractor must obtain IRB approval and maintain all necessary Human Subjects Research certifications. Interested parties should note the response deadline of December 4, 2026.

Defense Health Agency

POSTED

DEADLINE

Blood-Based Biomarker Validation & ScalingThis subcontract focuses on the validation and scaling of blood-based biomarkers to support prime contractors within the Defense Health Agency Alzheimer’s Research Program. The scope of work involves performing detailed laboratory analysis of blood samples, validating the sensitivity and specificity of assays, and establishing scalable testing protocols. These operations must utilize Simoa equipment and biobanking systems while adhering strictly to GLP standards and maintaining CLIA certification. The project is managed under the Department of Defense and is centered in Frederick, Maryland. The primary objective is the delivery of validated, scalable biomarker assays and protocols to advance research goals. Interested parties should note the response deadline of December 4, 2026, and the classification of the work under NAICS code 541714.

Defense Health Agency

POSTED

DEADLINE

RFI Alzheimer’s Research Program (AZRP) Public

Solicitation # HT9427RFI2027AZRP

The Defense Health Agency, through the Congressionally Directed Medical Research Programs, has issued a Request for Information under solicitation number HT9427RFI2027AZRP to gather strategic feedback for the fiscal year 2027 Alzheimer’s Research Program. The primary objective is to identify research focus areas and funding opportunities aimed at mitigating the impact of Alzheimer's and related dementias, specifically those associated with traumatic brain injury, military service, and diverse risks. The program seeks to improve the quality of life for Service Members, Veterans, and their families by funding solution-oriented research, including the development of digital and blood-based biomarkers for early diagnosis and the creation of precision prevention strategies. This action is strictly for information and planning purposes and does not constitute a formal solicitation, request for proposals, or request for quotations. No contracts will be awarded based on this announcement, and FY27 funds have not yet been appropriated. Interested parties from academia, industry, non-profit organizations, and federal agencies are invited to provide feedback via Survey Monkey by December 4, 2026. Respondents are cautioned not to submit proprietary or sensitive information through the survey portal as it cannot be protected. The effort is categorized under NAICS code 541714 and is managed by the Department of Defense in Fort Detrick, Maryland.

Defense Health Agency

POSTED

DEADLINE

Traumatic Brain Injury and Psychological Health Research Program Public Request for Information

Solicitation # HT9427RFI2027TBIPHRP

The Defense Health Agency, under the Department of Defense and the Congressionally Directed Medical Research Programs, has issued a Request for Information under solicitation number HT9427RFI2027TBIPHRP. This action is strictly for strategic planning and is not a formal solicitation, request for proposals, or request for quotations. The primary objective is to gather feedback from academia, industry, non-profit organizations, and the public to inform the research focus areas and funding opportunities for the fiscal year 2027 Traumatic Brain Injury and Psychological Health Research Program. The program aims to optimize the prevention, assessment, and treatment of psychological health conditions and traumatic brain injuries to benefit Service Members, Veterans, and the general public. Interested parties are asked to provide input on research gaps and funding priorities, specifically regarding the prevention, screening, diagnosis, and treatment of these conditions. Responses must be submitted via Survey Monkey by December 11, 2026. Because the government cannot protect proprietary or sensitive information submitted through the survey platform, such data should not be included. This inquiry does not commit the program to incorporating the feedback into future funding opportunities, and no contract will be awarded based on this specific announcement. All inquiries regarding this RFI should be directed to Patrick M. Younkins.

Defense Health Agency

POSTED

DEADLINE

Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Solicitation # 75A50126R00001_RFP_NPIVS_27

The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. The objective is to maintain a permanent readiness posture against high-threat influenza and other viruses with pandemic potential. Selected contractors will provide essential services, personnel, and facilities to produce vaccines, antigens, and adjuvants, while generating the necessary analytical, nonclinical, clinical, and chemistry, manufacturing, and controls data for FDA submission to support rapid regulatory decisions. To be eligible, offerors must be capable of producing vaccines against influenza strains with pandemic potential and demonstrate success through a U.S. influenza vaccine license or a submitted Biologics License Application. The government intends to award contracts to four offerors based on the Highest Technically Rated Offerors with a Fair and Reasonable Price methodology. Evaluation focuses on capabilities, past performance, and price, with a minimum requirement of a High Confidence rating for technical capabilities. The contract structure consists of a 60-month base period and a 60-month option period, with a minimum guarantee of 50,000 dollars. Key requirements include the development of comprehensive manufacturing and business continuity plans, adherence to strict ASPR security and cybersecurity standards, and the use of the Department of Treasury Invoice Processing Platform for quarterly invoicing. Performance is monitored through a BARDA dose tracker, and final acceptance is triggered by the submission of a final report and updated dose tracking data.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

USDA SBIR/STTR Topic 8.2 — Plant Production and Protection - Biology

Solicitation # USDA-NIFA-TOPIC-8.2

The USDA National Institute of Food and Agriculture is soliciting proposals under Topic 8.2 for Plant Production and Protection - Biology. This initiative focuses on advancing crop production and protection through the development of innovative plant breeding methods, diagnostic technologies for diseases, and the creation of new food and non-food crop plants. Research efforts are directed toward improving plant characteristics to mitigate biotic and abiotic stresses, developing new genotypes for commercial applications, and creating tools to support the health of natural and domesticated pollinators. This opportunity is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to companies with fewer than 500 employees. Managed by the United States Department of Agriculture, the program is led by Dr. Christopher Philips. Interested parties can find further details and application guidelines through the NIFA website.

National Institute of Food and Agriculture

POSTED

DEADLINE

Quantitative Analysis of Longitudinal MR Images

Solicitation # 75N98027R00005

Solicitation 75N98027R00005 is a Sources Sought notice issued by the National Institute on Aging (NIA) to identify qualified companies capable of performing quantitative analysis of longitudinal Magnetic Resonance (MR) images. The project supports the Baltimore Longitudinal Study of Aging (BLSA) by processing 300 newly acquired MR datasets to characterize brain aging trajectories and identify predictors of cognitive decline and Alzheimer’s disease. The selected contractor will provide specialized, non-commercial services to deliver global and regional tissue volumes, lesion quantification, and machine learning-derived scores, such as SPARE-AD, while ensuring longitudinal consistency with data acquired since 1994. The anticipated contract will be a firm fixed price award with a period of performance of one year. Key deliverables include quantitative volumetric results, intermediate processing files, and registration maps for PET overlay, submitted every six months, concluding with a final report. Technical requirements emphasize the use of established image analysis tools and adherence to FISMA/FedRAMP-aligned data security controls to protect participant confidentiality. Interested respondents must submit a capability statement by November 9, 2026, to Contract Specialist Sneha Singh. The submission must be limited to ten pages and include the company's Unique Entity ID, NAICS code 541714, professional qualifications of personnel, and any applicable GSA schedules or government-wide acquisition contracts. Small businesses are encouraged to respond to this market research effort to help the government determine the appropriate acquisition method.

National Institutes Of Health Olao

POSTED

DEADLINE

Q--AMPLICON SEQUENCING SERVICES

Solicitation # 140G0226Q0047

The Department of the Interior, through the USGS OAG Denver Acquisition Branch, is soliciting quotations for a Blanket Purchase Agreement (BPA) to provide next-generation amplicon sequencing services for the Michigan Bacteriological Research Laboratory. The agreement has a not-to-exceed value of $250,000 over a five-year period of performance from September 17, 2026, to September 16, 2031. The scope of work includes non-personal services such as library preparation for 16S V4 amplicon sequencing, library pooling, and sequencing using Illumina MiSeq or AVITI platforms to support research on bacterial pathogens, antibiotic resistance, and microbial ecology. Key deliverables include demultiplexed raw data and reporting metrics, with a required delivery turnaround of 60 business days from sample receipt. Award decisions will be based on technical and priced factors, with non-priced factors carrying significantly more weight. Technical evaluations will focus on the contractor's on-site equipment, personnel experience, quality control procedures, business establishment, and a capabilities narrative. Offerors must also provide two customer references from the last five years. The contract is subject to various federal regulations, including specific security prohibitions regarding certain telecommunications equipment and the requirement for electronic invoicing through the Invoice Processing Platform System. Quotations are due by November 5, 2026, and must be submitted via email to the primary point of contact.

Ofc Of Acquisition Grants-Denver

POSTED

DEADLINE

ARPA-H Emerging Health Innovators (EHI) Initiative

Solicitation # ARPA-H-SOL-26-150

The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, seeks to identify and engage early-career investigators to develop cutting-edge biomedical, health, and community-engaged research. This opportunity is open to researchers from academic, nonprofit, and industry organizations, provided the Principal Investigator is within eight years of completing their first terminal degree. The initiative covers 16 specific topic areas, including AI in life sciences, brain stimulation, and human tissue platforms. Awards are issued as Other Transaction (OT) agreements, which are not subject to the Federal Acquisition Regulation (FAR). The selection process is a two-step submission involving an initial anonymized Solution Summary and a subsequent Full Proposal for selected candidates. Successful awards have a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a 24-month base period capped at 700,000 dollars and an optional 12-month Director's Award period capped at 350,000 dollars. Payments are structured as fixed payments triggered by the completion of 12 discrete, measurable milestones. Full proposals are evaluated based on technical merit, innovativeness, feasibility, alignment with the ARPA-H mission to accelerate health outcomes, and price reasonableness. Administrative requirements include mandatory registration in SAM.gov and the use of the ARPA-H Solutions site for all submissions. Proposers must adhere to strict formatting templates for technical and management proposals, milestone schedules, and national policy requirements, including disclosures regarding organizational conflicts of interest and research security. Performance is monitored through a formal inspection and acceptance process where the government reviews deliverables within 14 calendar days. The tentative award start date is June 30, 2027, with full proposals due by February 10, 2027.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

In Vivo Biodistribution Studies and Bioluminescence ImagingThis subcontract, titled In Vivo Biodistribution Studies and Bioluminescence Imaging, supports biotechnology projects for the Department of Veterans Affairs at the Harry S Truman Memorial Veterans Hospital. The selected provider will conduct animal studies to evaluate AAV vector specificity and off-target transduction. Key technical responsibilities include administering vectors to animal models, utilizing bioluminescence imaging via IVIS to track localization, and performing tissue harvesting for qPCR analysis to generate comprehensive biodistribution data reports. The work will be performed in Columbia, Missouri, and requires strict adherence to AAALAC and FELASA health standards. This opportunity is categorized under NAICS code 541714 and is managed by Rpo East. Interested parties should note the response deadline of November 4, 2026.

POSTED

DEADLINE

AAV Vector Binding and Internalization Testing (Kidney Tissue)This subcontract, issued by the Department of Veterans Affairs Rpo East for biotechnology projects at the Harry S Truman Memorial Veterans Hospital, involves specialized laboratory testing to verify the binding and internalization of AAV vectors. The selected provider will be responsible for preparing kidney tissue slices, incubating them with modified AAV vectors, and utilizing qPCR platforms, Agilent Fragment Analyzers, and fluorescence microscopy to analyze efficiency. All work must be performed in BSL-2 facilities, and the contractor is required to hold BSL-2 certification. The primary deliverable for this engagement is the provision of detailed validation reports focusing on internalization rates and binding affinity. The project is categorized under NAICS code 541714 and is based in Columbia, Missouri. Interested parties must respond by November 4, 2026.

Rpo East (36C24E)

POSTED

7 days ago

DEADLINE

in 7 days

AI Contract Overview

The contract seeks innovative approaches to advance the evaluation of botulinum neurotoxins (BoNT) by transitioning from traditional mouse-based bioassays to human-relevant in vitro systems. Specifically, it focuses on developing neuromuscular junction (NMJ) micro-physiological platforms that can accurately measure BoNT potency and assess the effectiveness of medical countermeasures while reducing animal testing. These in vitro systems should offer mechanistic insight into the toxin’s activity, including the ability to demonstrate recovery of neuronal signaling, which is critical for evaluating therapeutic interventions. The initiative is led by BARDA under the Department of Health and Human Services and is aimed at exploring whether these alternative platforms can eventually validate and potentially replace mouse potency and neutralization assays commonly used today. The solicitation, numbered SSN-BARDA-04202026 and posted in April 2026, encourages responses by mid-May 2026 from entities capable of advancing this technology. The effort aligns with growing ethical and regulatory interests in minimizing animal use in testing while enhancing the biological relevance and accuracy of BoNT assessment methods.

General Info

Develop human-relevant in vitro NMJ platforms to replace mouse BoNT assays for potency testing.

Agency

Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Washington, DC, USA

Set-Aside

NONE

Documents

RRPV_RFI_BoNT-NMJ+RFI.pdf

AI Contract Breakdown

Uniform Contract Format

Timeline

PhaseClosed

PostedApr 20

Sources Sought

Response DeadlineMay 11

Deadline has passed

Submission Closed

05/11/2026, 05:00:00 PM UTC

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Contacts2 people available

OfficeWASHINGTON, DC, 20515, USA

Organization / AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Office AddressWASHINGTON, DC, 20515, USA

Contacts

Kathy Garee

contact@example.gov

Yifan Yang

contact@example.gov

Full Description

Botulinum neurotoxins (BoNT/A–G) inhibit acetylcholine release at the neuromuscular junction through cleavage of SNARE proteins (e.g., SNAP-25, VAMP, syntaxin). Currently, BoNT characterization, including toxin potency and neutralization by medical countermeasures, is measured using mouse-based bioassays, primarily the Mouse Potency Assay (MPA) and Mouse Neutralization Assay (MNA), respectively.

There is increasing scientific, ethical, and regulatory interest in transitioning to human-relevant in vitro systems that can provide mechanistic insight while reducing reliance on animal testing. NMJ micro-physiological systems may provide a biologically relevant platform capable of measuring BoNT potency and evaluating countermeasure efficacy.

BARDA is interested in understanding whether NMJ-based in vitro platforms could support future development of validated assays capable of reducing and potentially replacing reliance on mouse bioassays for BoNT potency and neutralization measurements, with specific interest in systems that can show recovery of neuronal signaling and thereby be appropriate for medical countermeasures evaluation.